Approved as a once-weekly GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight-related health conditions, Wegovy entered the India Semaglutide market ahead of its patent expiry to counter rising competition from Eli Lillys Mounjaro
Additionally, adults with a BMI of 27 kg/m or greater (classified as overweight) may qualify if they have at least one weight-related medical condition, such as hypertension (high blood pressure), diabetes, or dyslipidemia (high cholesterol)
Initiation and titration should follow product-specific protocols: Ozempic: Begin with 0.25 mg weekly for 4 weeks, then increase to 0.5 mg weekly, with further titration to 1 mg and potentially 2 mg weekly as tolerated Wegovy: Begin with 0.25 mg weekly for 4 weeks, then increase monthly through 0.5 mg, 1 mg, 1.7 mg, to a maintenance dose of 2.4 mg weekly Rybelsus: Begin with 3 mg once daily for 30 days, then increase to 7 mg daily, with further titration to 14 mg daily as needed [7] [8] MS patients may benefit from slower titration schedules if gastrointestinal tolerability is problematic
A third mistake is using the wrong type of syringe
Someone expecting the appetite suppression of a 5mg dose might effectively be receiving 2.5mg or less, which could explain a sudden plateau in tirzepatide results
